[Treatment of solar urticaria: advantage of terfenadine]. 1989

M Jeanmougin, and J R Manciet, and J P Moulin, and J Civatte
Unité de photodermatologie, Hôpital Saint-Louis, Paris.

Solar urticaria is a rare photodermatosis, but it is extremely incapacitating and therapy is usually ineffective. Three patients who took a daily dose of 240 mg terfenadine were able to be normally exposed to sunlight. This efficacy was confirmed by photobiological tests. The minimal dose necessary to induce urticaria was increased at least three times. These results confirming recently published ones. Terfenadine at 240 mg per day seems to be the treatment of choice for solar urticaria because of its efficacy and excellent tolerance-especially as there is no sedative effect.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010787 Photosensitivity Disorders Abnormal responses to sunlight or artificial light due to extreme reactivity of light-absorbing molecules in tissues. It refers almost exclusively to skin photosensitivity, including sunburn, reactions due to repeated prolonged exposure in the absence of photosensitizing factors, and reactions requiring photosensitizing factors such as photosensitizing agents and certain diseases. With restricted reference to skin tissue, it does not include photosensitivity of the eye to light, as in photophobia or photosensitive epilepsy. Actinic Reticuloid Syndrome,Dermatitis, Actinic,Photodermatitis,Chronic Actinic Dermatitis,Photosensitization,Actinic Dermatitides,Actinic Dermatitides, Chronic,Actinic Dermatitis,Actinic Dermatitis, Chronic,Actinic Reticuloid Syndromes,Chronic Actinic Dermatitides,Dermatitides, Actinic,Dermatitides, Chronic Actinic,Dermatitis, Chronic Actinic,Disorder, Photosensitivity,Disorders, Photosensitivity,Photodermatitides,Photosensitivity Disorder,Reticuloid Syndrome, Actinic,Reticuloid Syndromes, Actinic,Syndrome, Actinic Reticuloid,Syndromes, Actinic Reticuloid
D005260 Female Females
D006634 Histamine H1 Antagonists Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. Antihistamines, Classical,Antihistaminics, Classical,Antihistaminics, H1,Histamine H1 Antagonist,Histamine H1 Receptor Antagonist,Histamine H1 Receptor Antagonists,Histamine H1 Receptor Blockaders,Antagonists, Histamine H1,Antagonists, Histamine H1 Receptor,Antihistamines, Sedating,Blockaders, Histamine H1 Receptor,First Generation H1 Antagonists,H1 Receptor Blockaders,Histamine H1 Blockers,Receptor Blockaders, H1,Antagonist, Histamine H1,Classical Antihistamines,Classical Antihistaminics,H1 Antagonist, Histamine,H1 Antagonists, Histamine,H1 Antihistaminics,Sedating Antihistamines
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001559 Benzhydryl Compounds Compounds which contain the methyl radical substituted with two benzene rings. Permitted are any substituents, but ring fusion to any of the benzene rings is not allowed. Diphenylmethyl Compounds,Compounds, Benzhydryl,Compounds, Diphenylmethyl
D014581 Urticaria A vascular reaction of the skin characterized by erythema and wheal formation due to localized increase of vascular permeability. The causative mechanism may be allergy, infection, or stress. Hives,Urticarial Wheals,Urticarial Wheal,Urticarias,Wheal, Urticarial,Wheals, Urticarial
D016593 Terfenadine A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME. Balkis Saft Spezial,Cyater,Hisfedin,RMI-9918,Rapidal,Seldane,Teldane,Terfedura,Terfemundin,Terfenadin AL,Terfenadin Heumann,Terfenadin Stada,Terfenadin Von Ct,Terfenadin-Ratiopharm,Terfenidine,Ternadin,Triludan,alpha-(4-(1,1-Dimethylethyl)phenyl)-4-(hydroxydiphenylmethyl)-1-piperdinebutanol,RMI 9918,RMI9918,Terfenadin Ratiopharm

Related Publications

M Jeanmougin, and J R Manciet, and J P Moulin, and J Civatte
March 1988, Journal of the American Academy of Dermatology,
M Jeanmougin, and J R Manciet, and J P Moulin, and J Civatte
February 1988, Photo-dermatology,
M Jeanmougin, and J R Manciet, and J P Moulin, and J Civatte
April 1993, Journal of the American Academy of Dermatology,
M Jeanmougin, and J R Manciet, and J P Moulin, and J Civatte
March 1984, Clinical allergy,
M Jeanmougin, and J R Manciet, and J P Moulin, and J Civatte
April 1991, Photodermatology, photoimmunology & photomedicine,
M Jeanmougin, and J R Manciet, and J P Moulin, and J Civatte
October 1986, Journal of the American Academy of Dermatology,
M Jeanmougin, and J R Manciet, and J P Moulin, and J Civatte
June 1986, Photo-dermatology,
M Jeanmougin, and J R Manciet, and J P Moulin, and J Civatte
October 1988, Cutis,
M Jeanmougin, and J R Manciet, and J P Moulin, and J Civatte
January 1990, Allergy,
M Jeanmougin, and J R Manciet, and J P Moulin, and J Civatte
January 2003, Dermatologic therapy,
Copied contents to your clipboard!